27 completed, 25 recruiting, 13 active not recruiting, 8 terminated. 59 Phase 2, 23 Phase 1, 9 Phase 3, 1 Early Phase 1, 1 Phase 4.
Follow relatlimab: new trials by email Literature Review of relatlimab trials Research Report on relatlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer. Nivolumab, Gemcitabine, Cisplatin - Advanced Biliary Tract Cancer(BTC) | Phase 2 | Withdrawn | National Health Research Institutes, Taiwan | 2026-12-01 | 2026-07-02 | |
| A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India Nivolumab + Relatlimab - Unresectable Melanoma, Metastatic Melanoma | Phase 4 | Not yet recruiting | Bristol-Myers Squibb | 40 | 2026-11-15 | 2026-08-12 |
| Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis Nivolumab and Relatlimab, Melphalan - Metastatic Melanoma, Liver Metastases | Phase 1 / Phase 2 | Recruiting | University of Wisconsin, Madison | 15 | 2026-10-01 | 2026-09-29 |
| ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab Nivolumab, Relatlimab, Ipilimumab - Metastatic Melanoma, Advanced Melanoma | Phase 2 | Recruiting | NYU Langone Health | 90 | 2026-04-13 | 2026-08-24 |
| Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) Ipilimumab 3mg/kg and nivolumab 1mg/kg, Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg, Nivolumab 480mg and relatlimab 160mg - Cutaneous Melanoma, Mucosal Melanoma | Phase 2 | Recruiting | Melanoma Institute Australia | 494 | 2026-02-09 | 2026-02-19 |
| Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab Nivolumab, Relatlimab, TMZ - Newly Diagnosed Glioblastoma | Phase 2 | Recruiting | Duke University | 92 | 2025-11-28 | 2026-09-17 |
| Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma Fianlimab + Cemiplimab, Relatlimab + Nivolumab - Locally Advanced Melanoma | Recruiting | John Kirkwood | 20 | 2025-11-19 | 2025-11-26 | |
| Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma Nivolumab, Relatlimab plus Nivolumab - Basal Cell Carcinoma | Phase 2 | Recruiting | University of California, San Diego | 30 | 2025-08-21 | 2026-07-28 |
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide) - Melanoma (Skin Cancer), Melanoma Stage IIIB-IV | Phase 2 / Phase 3 | Recruiting | Linnaeus Therapeutics, Inc. | 135 | 2025-08-06 | 2026-04-22 |
| Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab Nivolumab + relatlimab, Nivolumab + ipilimumab - Melanoma | Completed | Bristol-Myers Squibb | 100 | 2025-05-11 | 2025-11-12 | |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma IMA203, nivolumab plus relatlimab, lifileucel - Melanoma, Cutaneous Malignant | Phase 3 | Recruiting | Immatics US, Inc. | 360 | 2025-01-14 | 2026-08-18 |
| Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) Nivolumab, Relatlimab, Ipilimumab - Melanoma | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-12-31 | 2026-08-28 |
| Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database Nivolumab + Relatlimab, Nivolumab + Ipilimumab, Immunotherapy monotherapy - Advanced Melanoma | Completed | Bristol-Myers Squibb | 678 | 2024-11-29 | 2025-07-23 | |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma Biopsy Procedure, Biospecimen Collection, Lomustine - Progressive Glioblastoma, Recurrent Glioblastoma | Phase 2 | Suspended | National Cancer Institute (NCI) | 184 | 2024-11-08 | 2026-10-19 |
| A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% Nivolumab, Relatlimab, Pembrolizumab - Non-small Cell Lung Cancer | Phase 3 | Recruiting | Bristol-Myers Squibb | 1000 | 2024-10-07 | 2026-10-23 |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Biospecimen Collection, Bone Scan, Carboplatin - Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 156 | 2024-07-15 | 2026-10-26 |
| VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab - Advanced Melanoma | Phase 3 | Recruiting | Replimune, Inc. | 400 | 2024-07-11 | 2026-07-15 |
| Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination - Cutaneous Squamous Cell Carcinoma | Phase 2 | Recruiting | Melanoma Institute Australia | 20 | 2024-06-21 | 2026-07-08 |
| IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) Brenetafusp, Nivolumab, Nivolumab + Relatlimab - Advanced Melanoma | Phase 3 | Recruiting | Immunocore Ltd | 680 | 2024-06-05 | 2026-02-25 |
| Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma Nivolumab, Nivolumab + Relatlimab, Ipilimumab - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 90 | 2024-05-17 | 2026-04-01 |
Showing 20 of 82. Sign in to see all of them.
Melanoma (22) · Neoplasms (6) · Carcinoma, Hepatocellular (5) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (4) · Recurrence (4) · Stomach Neoplasms (4) · Colonic Neoplasms (3) · Liver Neoplasms (3) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Squamous Cell Carcinoma of Head and Neck (3) · Urinary Bladder Neoplasms (3) · Uveal Melanoma (3) · Brain Neoplasms (2)
Bristol-Myers Squibb (27) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (5) · Melanoma Institute Australia (4) · Dan Zandberg (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · John Kirkwood (2) · NYU Langone Health (2) · The Netherlands Cancer Institute (2) · University Hospital, Essen (2) · Carlo Contreras (1) · Celgene (1) · Duke University (1) · Elizabeth Davis (1)
United States (62) · Australia (23) · France (19) · Germany (19) · Spain (19) · Canada (18) · Italy (18) · United Kingdom (15) · Austria (12) · Belgium (12) · Netherlands (11) · Switzerland (11) · Poland (10) · Brazil (9) · Mexico (9)
Dung Le, MD (2) · Georgina Long (2) · Vincent Lam, MD (2) · Ahmad Tarhini, MD, PhD (1) · Arun Singh (1) · Brigette B Ma (1) · Carlo M Contreras, MD (1) · Cedrik Britten, M.D. (1) · Dan P Zandberg, MD (1) · Dan Zandberg, MD (1) · Elizabeth Davis, MD (1) · Evan J Lipson, M.D. (1) · Georgina V Long (1)
PMID 26586415, PMID 28734759, PMID 29355075, PMID 30170630, PMID 31487218, PMID 32251400, PMID 32324435, PMID 32463741, PMID 33048619, PMID 33277223, PMID 34083421, PMID 34515338, PMID 34606846, PMID 34637336, PMID 34986285, PMID 35133871, PMID 35138919, PMID 35969233, PMID 36328377, PMID 36351402, PMID 36628573, PMID 36648215, PMID 36719749, PMID 36780608, PMID 37053535, PMID 37167764, PMID 37322121, PMID 37934000, PMID 38320023, PMID 38340723, PMID 38504015, PMID 38591867, PMID 38608691, PMID 38689060, PMID 38821718, PMID 38838311, PMID 38838316, PMID 39187595, PMID 39278994, PMID 39666929, PMID 39671533, PMID 39693587, PMID 39889250, PMID 39913886, PMID 40010775, PMID 40016450, PMID 40030000, PMID 40340830, PMID 40389374, PMID 40513285
2018 (4), 2023 (4), 2016 (2), 2019 (2), U10CA180820 (2), U10CA180821 (2), 2015 (1), P50CA062924 (1), U10CA180868 (1), U24CA196172 (1)